Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit

A Philadelphia jury on Tuesday hit Johnson & Johnson with an $8 billion verdict over its marketing of the anti-psychotic drug Risperdal, siding with a Maryland man who argued that the health care giant downplayed risks that the drug could lead to breast growth in boys.
(source: nytimes.com)

(No Ratings Yet)

Loading...